MIDDLE EAST AND TURKEY CHRONIC LIVER DISEASE (CLD) THERAPEUTICS MARKET ANALYSIS

Middle East and Turkey Chronic Liver Disease (CLD) Therapeutics Market, by Disease Type (Hepatitis, Alcohol Induced Liver Disease, Liver Cancer, Fatty Liver Disease, and Others), by Drug Class (Chemotherapy Drugs, Targeted therapy, Vaccines, Immunoglobulin, and Others), by Route of Administration (Oral and Parenteral), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Country (Turkey, Saudi Arabia, Israel, UAE, Egypt, and Rest of Middle East and Turkey) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Published In : Feb 2022
Code : CMI4920
Pages :211
Formats :
Excel and PDF
Industry : Pharmaceutical

Leading Companies

Key Players

Major players operating in the Middle East and Turkey chronic liver disease (CLD) therapeutics market include Hoffmann-La Roche AG, Gilead Sciences, Inc., Intercept Pharmaceuticals, Inc., Swedish Orphan Biovitrum AB, GlaxoSmithKline Plc, Sanofi S.A, Merck & Co., Inc., AbbVie Inc., Abbott Laboratories, AstraZeneca plc, and Pfizer Inc.

Middle East and Turkey Chronic Liver Disease (CLD) Therapeutics Market Report Snapshots